Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …

Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism,
is a chronic illness that affects nearly 10 million people every year worldwide. Strong …

C-reactive protein (CRP) is a member of the highly conserved pentraxin superfamily of
proteins and is often used in clinical practice as a marker of infection and inflammation …

Rheumatoid arthritis (RA) is a chronic autoimmune joint disease with persistent systemic
inflammation. Patients with RA suffer from joint pain and physical disability, but have their …

within the leg or pelvic veins, and approximately half of all deep-vein thrombi embolize to the
lungs. 1 The annual incidence of pulmonary embolism worldwide is approximately 1 in 1000 …

No clinical prediction model has been specifically developed or validated to identify patients
with unprovoked venous thromboembolism (VTE) who are at high risk of major bleeding …

Glucocorticoids are potent anti-inflammatory agents that are widely used for the treatment of
many inflammatory, autoimmune, and neoplastic disorders. However, their beneficial effect …

Anticoagulation therapy is the first line and drug of choice for both the treatment and
prophylaxis of venous thromboembolism (deep vein thrombosis and/or pulmonary …

Background The risk of venous thromboembolism (VTE) following total hip arthroplasty
(THA) and total knee arthroplasty (TKA) is 1.0% to 1.5%, despite uniform …

Venous thromboembolism, which includes deep venous thrombosis (DVT) and pulmonary
embolism, is the third most common vascular disease in the world and seriously threatens …